Skip to main content

Outage notice:

We have restored nearly all systems affected by the global information outage, and welcome patients to visit our Patient Service Centers. To reschedule a missed appointment, please visit our online scheduling site.   

Hide

Diabetes & prediabetes

First, know the risk with earlier diagnostic insight

As obesity rates continue to rise and the US contends with a growing aging population, the need for diabetes risk identification, prevention, and management is more critical than ever.1

Quest Diagnostics offers a comprehensive array of laboratory testing for diabetes to help you manage the disease in all of your patients, no matter where they are on the care continuum, ensuring continuity of care.

Identify insulin resistance, metabolic syndrome, prediabetes, and diabetes risk early—and in more patients—to help prevent or slow progression of the disease.

Learn more about early diagnostic insights

Learn more about diabetes and prediabetes risk

Start the right treatment plan with a differential diagnosis that goes beyond diabetes type 1 and type 2, including latent autoimmune diabetes in adults (LADA) and monogenic diabetes (MODY).

Learn more about making a differential diagnosis

Rely on our testing based on guidelines issued by the American Diabetes Association (ADA) to effectively monitor and manage diabetes patients and help them delay or avoid the potential for complications.

Learn more about monitoring diabetes

Defining the intersection of chronic conditions: a prevention-focused approach to cardiometabolic disease

With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.

Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.

  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,stage 4-5 CKD,3 and NAFLD.4
  • Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.5
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.6 The leading causes of end-stage renal disease are diabetes and hypertension.7
  • More than 75% of those who have T2DM have NAFLD.8

A comprehensive range of testing

The power of Quest


 

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.    
 

References

  1. CDC. Maps of diagnosed diabetes and obesity in 1994, 2000, and 2015. Published April 2017. Accessed July 18, 2018. www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf
  2. Einarson,TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(83). doi: 10.1186/s12922-018-0728-6
  3. Benjamin EJ, Virani SS, Callaway CW, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492. doi:10.1161/CIR.0000000000000558
  4. Golabi P, Fukui N, Paik J, et al. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2019;3(8):1050-1060. doi: 10.1002/hep4.1387
  5. Fox CS, Sullivan L, D’Agostino R, et al. The significant effect of diabetes duration on coronary heart disease mortality. Diabetes Care. 2004;27(3):704-708. doi:10.2337/diacare.27.3.704
  6. Penn MS, Klemes AB. Multimarker approach for identifying and documenting mitigation of cardiovascular risk. Future Cardiol. 2013;9(4):497-506. doi:10.2217/fca.13.27
  7. Ikonomidis I, Mihalakeas CA, Lekakis J, et al. Multimarker approach in cardiovascular risk prediction. Dis Markers. 2009;26(5-6):273-285. doi:10.3233/DMA-2009-0633
  8. Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011; 9(3): 321–328. doi:10.1586/erc.11.15

Get ahead of type 2 diabetes risk

Take a proactive approach to preventing, diagnosing, and managing diabetes at every stage of your patients’ care with the help of diagnostic insights.

Learn More